Skip to content

Study · Randomized controlled trial · n = 246 · 1992

4 results

Role of octreotide in the prevention of postoperative complications following pancreatic resection.

Büchler M, Friess H, Klempa I, Hermanek P, Sulkowski U, Becker H, Schafmayer A, Baca I, Lorenz D, Meister R

American journal of surgery1 Jan 1992Cited by 276 (Europe PMC)

PMID1733360 (opens in a new tab)DOI10.1016/0002-9610(92)90264-r (opens in a new tab)PepBankPUB-01733360
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    After pancreatic surgery, mortality within 90 days was 3.2% with octreotide versus 5.8% with placebo, with 4.5% overall mortality.

    In plain wordsAfter pancreatic surgery, mortality was numerically lower with octreotide than placebo within 90 days.

    Peptide
    Octreotide
    Outcome
    DecreaseMortality within 90 days
    Study

    n = 246

    Comparator
    Placebo
    Outcome group
    Mortality · Gastrointestinal
    Studied dose
    3 x 100 micrograms · subcutaneous · 7 days perioperativelyAs given in this study (human).

    Measurements

    Mortality within 90 days
    3.2%
    octreotide group
    Mortality within 90 days
    5.8%
    placebo group
    Overall mortality within 90 days
    4.5%
    both groups combined

    Source sentences

    Summary
    The overall mortality rate within 90 days was 4.5%, with 3.2% in the octreotide group and 5.8% in the placebo group.
    2 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, multicenter trial in 246 patients undergoing major elective pancreatic surgery.
    Summary · context
    Patients received octreotide (3 x 100 micrograms) or placebo subcutaneously for 7 days perioperatively.
  2. 02HumanRandomized controlled trialSafety outcome

    After pancreatic surgery, complications affected 32% (40 of 125) with octreotide versus 55% (67 of 121) with placebo (p less than 0.005).

    In plain wordsAfter pancreatic surgery, complications were less frequent with octreotide than placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseOverall complications
    Study

    n = 246

    Comparator
    Placebo
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    3 x 100 micrograms · subcutaneous · 7 days perioperativelyAs given in this study (human).

    Measurements

    Complication rate
    32%
    octreotide group, 40 of 125 patients
    Complication rate
    55%
    placebo group, 67 of 121 patients
    p-value
    < 0.005 p
    octreotide versus placebo

    Source sentences

    Summary
    The complication rate was 32% in the patients receiving octreotide (40 of 125 patients) and 55% in patients receiving placebo (67 of 121 patients) (p less than 0.005).
    2 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, multicenter trial in 246 patients undergoing major elective pancreatic surgery.
    Summary · context
    Patients received octreotide (3 x 100 micrograms) or placebo subcutaneously for 7 days perioperatively.
  3. 03HumanRandomized controlled trialSafety outcome

    In high-risk pancreatic surgery patients, complications affected 38% (26 of 68) with octreotide versus 65% (46 of 71) with placebo (p less than 0.01).

    In plain wordsIn high-risk pancreatic surgery patients, complications were less frequent with octreotide than placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseHigh-risk stratum complications
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    3 x 100 micrograms · subcutaneous · 7 days perioperativelyAs given in this study (human).

    Measurements

    Complication rate
    38%
    octreotide group, high-risk stratum, 26 of 68 patients
    Complication rate
    65%
    placebo group, high-risk stratum, 46 of 71 patients
    p-value
    < 0.01 p
    octreotide versus placebo, high-risk stratum

    Source sentences

    Summary
    In the patients in the high-risk stratum, complications were observed in 26 of the 68 (38%) patients treated with octreotide and in 46 of 71 (65%) patients given placebo (p less than 0.01).
    2 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, multicenter trial in 246 patients undergoing major elective pancreatic surgery.
    Summary · context
    Patients received octreotide (3 x 100 micrograms) or placebo subcutaneously for 7 days perioperatively.
  4. 04HumanRandomized controlled trialSafety outcome

    In low-risk pancreatic surgery patients, complications affected 25% (14 of 57) with octreotide versus 42% (21 of 50) with placebo (p = NS).

    In plain wordsIn low-risk pancreatic surgery patients, complications were numerically less frequent with octreotide than placebo, without statistical significance.

    Peptide
    Octreotide
    Outcome
    DecreaseLow-risk stratum complications
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    3 x 100 micrograms · subcutaneous · 7 days perioperativelyAs given in this study (human).

    Measurements

    Complication rate
    25%
    octreotide group, low-risk stratum, 14 of 57 patients
    Complication rate
    42%
    placebo group, low-risk stratum, 21 of 50 patients

    Source sentences

    Summary
    Whereas in patients in the low-risk stratum, the complication rate was 25% (14 of 57 patients) in those treated with octreotide and 42% (21 of 50 patients) in patients given placebo (p = NS).
    2 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, multicenter trial in 246 patients undergoing major elective pancreatic surgery.
    Summary · context
    Patients received octreotide (3 x 100 micrograms) or placebo subcutaneously for 7 days perioperatively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT02920567

Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion

Saint Vincent's Hospital, Korean = 282Jan 2014 to est. Jul 2018

Periampullary Tumors

Trial pageClinicalTrials.govUpdated 30 Sept 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.